Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Biomedical Engineering
SJR: 0.207 SNIP: 0.376 CiteScore™: 0.79

ISSN Print: 0278-940X
ISSN Online: 1943-619X

Critical Reviews™ in Biomedical Engineering

DOI: 10.1615/CritRevBiomedEng.v37.i3.20
pages 259-281

Biomaterials, Fibrosis, and the Use of Drug Delivery Systems in Future Antifibrotic Strategies

Ryan J. Love
School of Biomedical Engineering, McMaster University, Canada
Kim S. Jones
School of Biomedical Engineering and Department of Chemical Engineering, McMaster University, Canada


All biomaterials, when implanted into the body, elicit an inflammatory response that evolves into fibrovascular tissue formation on and around the material. As a result, material scientists and tissue engineers should be concerned about host response to tissue-engineered constructs that have a biomaterial component, because the host response to this component will interfere with device function and reduce the lifespan of tissue engineering devices in vivo. The fibrotic response to biomaterials is not unlike pathological fibrosis of the liver, lung, kidney, and peritoneum in many ways: i) the presence of mononuclear leukocytes are common in the local environment of both pathological fibrosis and biomaterial-induced fibrosis even though cells of mesenchymal origin are responsible for laying the majority of the extracellular matrix; ii) paracrinesignaling molecules, such as transforming growth factor β1, are essential mediators of fibrosis, whether it is pathological or biomaterial induced; and iii) injury and/or the presence of foreign materials (including bacterial components, toxins, or man-made objects) are essential initiators for the development of the fibrotic response. This review discusses mechanisms and research methodology related to pathological fibrosis that is of interest to researchers focused on biomaterials. Potential research models for the study of fibrosis from the fields of biomaterials and drug delivery are also discussed, which may be of interest to scientists working on the pathology of fibrotic disease.

Articles with similar content:

Factors Affecting Drug and Gene Delivery: Effects of Interaction with Blood Components
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 3
Makiya Nishikawa, Mitsuru Hashida, Praneet Opanasopit
The Role of Tissue Engineering in Articular Cartilage Repair and Regeneration
Critical Reviews™ in Biomedical Engineering, Vol.37, 2009, issue 1-2
Jerry Hu, Kyriacos A. Athanasiou, Lijie Zhang
Phospholipids: A Novel Adjuvant in Herbal Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 5
Mohammed Shuaib Khan, K. Krishnaraj
Scaffolds for Tissue Engineering of Cartilage
Critical Reviews™ in Eukaryotic Gene Expression, Vol.12, 2002, issue 3
J. M. Bezemer, C. A. van Blitterswijk, J. Riesle, T. B. F. Woodfield, J. S. Pieper
Review Article: Fabricated Microparticles: An Innovative Method to Minimize the Side Effects of NSAIDs in Arthritis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 5
Shaivad Shabee Hulhasan Abadi, Afrasim Moin, Gangadharappa Hosahalli Veerabhadrappa